Research News
View articles by month and year
1–7 of 7 articles
-
Very Early Study Suggests Herceptin May Help Treat Some HER2-Negative Breast Cancers
A very early study done in mice suggests that Herceptin may effectively treat very small breast cancer tumors in bones, even though the original cancer was classified as HER2-negative.
-
Heart Problems Happen More Often Than Thought in Older Women After Herceptin Treatment
A large study has found that older women diagnosed with early-stage, HER2-positive breast cancer treated with Herceptin have a higher risk of heart failure than women who didn’t get Herceptin.
-
One Year of Herceptin Best for Reducing Recurrence Risk of Early-Stage HER2-Positive Disease
Results from two studies confirm that 1 year of Herceptin, rather than 2 years or 6 months, after surgery seems to be best for reducing recurrence risk in women diagnosed with HER2-positive early-stage breast cancer.
-
Experimental Iniparib Increases Survival Only Slightly in Metastatic Triple-Negative Disease
A large study found that iniparib didn't improve survival in women diagnosed with metastatic triple-negative breast cancer, which contradicts results from earlier studies.
-
Experimental Iniparib Shows Promise in Treating Advanced-Stage Disease
A small, early study suggests that some advanced-stage cancers may respond to an experimental combination of iniparib and Camptosar.
-
Even Small HER2-Positive Cancers Have Higher Recurrence Risk
Small (1 cm or smaller), early-stage, HER2-positive breast cancers are more likely to come back (recur) and spread to parts of the body away from the breast (metastasize) than small, early-stage HER2-negative breast cancers, which suggests that treating these cancers with Herceptin (chemical name: trastuzumab) may make sense.
-
Malignant Stem Cells Seem to Make HER2-Positive Cancers Grow
HER2-positive breast cancers seem to have a large number of abnormal stem cells, which make the cancers grow and spread.
1–7 of 7 articles
